Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

NCT05450965 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT05450965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05450965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Recruiting
Start date
July 19, 2022
Completion date
November 30, 2027
Enrollment
37 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung carcinoma, small-cell lung cancer